We represented Quest Diagnostics (NYSE: DGX) in its acquisition of Cleveland HeartLab. The acquisition combines the expertise of Cleveland HeartLab’s personalized evaluation of heart disease risk based on inflammation and other markers with Quest’s Cardio IQ® lipid particle analysis and genetic and metabolic testing leadership. In connection with the acquisition, Quest Diagnostics and Cleveland Clinic have also finalized a strategic collaboration intended to speed the commercialization of emerging innovations at Cleveland Clinic, including its Lerner Research Institute. Terms of the transaction were not publicly disclosed.
Quest Diagnostics is the world’s leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions.